Zidesamtinib Secures Niche FDA Approval, But Critical Data Gaps Cloud Competitive Battle in ROS1+ NSCLC

FDA Approves GSK's Jideytro for ROS1-Positive Lung Cancer

The FDA has approved GSK’s ROS1 inhibitor zidesamtinib, branded as Jideytro, for patients with advanced non-small cell lung cancer (NSCLC) who are positive for the ROS1 gene fusion and have undergone prior ROS1-directed therapy. This approval marks GSK's entry into the lung cancer market and provides a swift return on its recent $10.6 billion acquisition of Nuvalent Bio. The regulatory decision was supported by data from the Phase 1/2 ARROS-1 clinical trial, which demonstrated an overall response rate of 44% and durable responses, including in patients with brain metastases and ROS1 resistance mutations.

• Jideytro's approval by the FDA establishes GSK's presence in the lung cancer therapeutic area. The drug is specifically indicated for advanced NSCLC patients with ROS1 gene fusion who have previously received ROS1-directed therapy, addressing a critical unmet need in this patient population.
• Clinical efficacy data from the single-arm Phase 1/2 ARROS-1 trial underpinned the approval, showing a 44% overall response rate. The drug also demonstrated significant and durable responses, with a duration of response rate of 82% at six months and 69% at 12 months, even in challenging cases like patients with brain metastases and ROS1 resistance mutations.
• The approval delivers a rapid return on GSK's strategic $10.6 billion acquisition of Nuvalent Bio, completed last week. Beyond zidesamtinib, the acquisition also brought other promising lung cancer assets into GSK's pipeline, including the ALK blocker neladalkib, currently under FDA review, and the early-stage HER2-altered NSCLC candidate NVL-330, both of which GSK believes hold multi-blockbuster potential.

Jideytro: Addressing Unmet Needs in Advanced ROS1+ NSCLC

Despite high initial response rates to first-generation ROS1 TKIs like crizotinib, disease relapse is essentially inevitable, with resistance emerging after a median time-to-progression of 5.5–20 months. The clinical management of patients post-progression remains challenging due to acquired resistance mechanisms, limited CNS penetration of earlier agents, and persistent gaps in tolerability and sequencing strategy.

• On-target resistance via ROS1 kinase domain mutations is a primary driver of crizotinib failure, most notably the solvent-front mutation ROS1 G2032R, along with G2026M, S1986Y/F, D2033N, F2004C, and L2026M; the recently characterized L2086F mutation (2024) confers resistance even to later-generation type I TKIs (crizotinib, entrectinib, lorlatinib, repotrectinib, taletrectinib), though it retains sensitivity to type II agents like cabozantinib and merestinib.

• Off-target/bypass signaling pathways also contribute to resistance, including MET kinase domain mutations (e.g., D1228N), EGFR pathway activation (observed in SLC34A2-ROS1 models), and induced VEGFR2 signaling following targeted therapy exposure.

• TP53 co-mutations, among the most frequently altered genes in NSCLC, have been associated with reduced responsiveness to ROS1-targeted therapy across multiple studies.

• CNS efficacy remains a critical limitation, as earlier-generation TKIs demonstrate limited blood-brain barrier penetration, leaving brain metastases inadequately controlled in a substantial subset of patients.

• Sequential TKI therapy shows clinical benefit but is not universally applied: among 29 patients with ROS1-rearranged NSCLC progressing on first-line TKI, only 37.9% received subsequent TKI therapy (e.g., lorlatinib), yielding a median second PFS of 5.5 months (95% CI, 4.1–9.1) and post-progression survival of 21.0 months (95% CI, 5.5–NR). Next-generation TKIs administered after progression achieved an ORR of 41.7%, median PFS of 12.7 months, and median OS of 17.0 months.

• Sequential ROS1 TKI use significantly improves overall survival compared with non-sequential approaches (NR vs. 16.1 months; HR, 0.26; 95% CI, 0.10–0.78; P = .017), underscoring the importance of optimized treatment sequencing.

• Tolerability concerns persist, particularly TRK-mediated off-target neurological toxicities associated with earlier agents, highlighting a need for more selective inhibitors.

• Emerging agents aim to address these gaps: repotrectinib has shown potent activity in both TKI-naive and resistant tumors, including those with G2032R mutations, while zidesamtinib—a highly selective next-generation ROS1 inhibitor—is designed to minimize TRK-related neurological toxicity and improve overall tolerability.

• Primary resistance to crizotinib, though less common, has also been reported in ROS1-rearranged NSCLC, with underlying mechanisms not yet well defined.

• Collectively, these findings highlight persistent unmet needs in managing resistance mutations, achieving durable CNS disease control, and refining treatment sequencing and combination strategies to sustain long-term disease control in advanced ROS1+ NSCLC.

Jideytro's Position in the ROS1+ NSCLC Landscape

Beyond zidesamtinib, the clinical pipeline includes other ROS1-targeted tyrosine kinase inhibitors for ROS1-positive non-small cell lung cancer. One notable competitor is taletrectinib, a potent and selective ROS1/pan-NTRK inhibitor that has shown preclinical activity against the G2032R solvent-front mutation. Data from Phase 1 dose-escalation studies highlight its efficacy in both TKI-naïve and crizotinib-pretreated patients, as summarized below.